(NYSE: LLY) Eli Lilly & Co's forecast annual revenue growth rate of 23.72% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.31%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.41%.
Eli Lilly & Co's revenue in 2025 is $45,042,700,000.On average, 7 Wall Street analysts forecast LLY's revenue for 2025 to be $56,721,364,997,298, with the lowest LLY revenue forecast at $55,470,789,451,497, and the highest LLY revenue forecast at $58,858,485,181,184. On average, 7 Wall Street analysts forecast LLY's revenue for 2026 to be $69,329,025,025,951, with the lowest LLY revenue forecast at $64,629,163,471,838, and the highest LLY revenue forecast at $75,469,023,116,576.
In 2027, LLY is forecast to generate $80,655,156,499,186 in revenue, with the lowest revenue forecast at $74,068,195,811,883 and the highest revenue forecast at $88,051,309,167,886.